Key result
Fixed-dose combinations of verapamil/trandolapril, atenolol/chlorthalidone, and lisinopril/hydrochlorothiazide significantly reduced sitting diastolic blood pressure compared to placebo (P=0.0001).
Why the study?
Do fixed-dose antihypertensive combinations (verapamil/trandolapril, atenolol/chlorthalidone, lisinopril/hydrochlorothiazide) reduce blood pressure compared to placebo in patients with essential hypertension?
Population
205 randomized patients with essential hypertension and supine diastolic blood pressure 101-114 mmHg.
Comparison
Fixed-dose combinations of sustained-release… vs Placebo
Design
RCT, assigned randomly, double-blind, placebo-controlled
Follow-up
8 weeks
Authors
Loading...
Supports fixed-dose combinations for BP lowering in essential hypertension; confirms comparable efficacy of verapamil/trandolapril to standard regimens.
RCT (n=205)
Double-blind
randomly assigned
Yes
Do fixed-dose antihypertensive combinations (verapamil/trandolapril, atenolol/chlorthalidone, lisinopril/hydrochlorothiazide) reduce blood pressure compared to placebo in patients with essential hypertension?
Mean Difference: 13 (95% CI 9–16)
p-value: p=0.0001
A low-dose combination of sustained-release verapamil and trandolapril is as effective as traditional beta-blocker/diuretic or ACE-inhibitor/diuretic combinations in reducing blood pressure in essential hypertension.
Leeuw et al. (1997) conducted an RCT in essential hypertension (n=205). sustained-release verapamil/trandolapril, atenolol/chlorthalidone, and lisinopril/hydrochlorothiazide vs. placebo was evaluated on Reduction in supine and standing blood pressures (MD 13, 95% CI 9-16, p=0.0001). Fixed-dose combinations of verapamil/trandolapril, atenolol/chlorthalidone, and lisinopril/hydrochlorothiazide significantly reduced sitting diastolic blood pressure compared to placebo (P=0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: